Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2023-06-20
Last Posted Date
2024-11-18
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
100
Registration Number
NCT05910801
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

First Posted Date
2023-06-13
Last Posted Date
2023-08-14
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
35
Registration Number
NCT05900882
Locations
🇨🇳

Nanjing First People's Hospital, Nanjing, Jiangsu, China

🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

🇨🇳

Taizhou People's Hospital, Taizhou, Jiangsu, China

and more 3 locations

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

First Posted Date
2023-06-12
Last Posted Date
2023-06-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
332
Registration Number
NCT05899621
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

First Posted Date
2023-06-06
Last Posted Date
2024-10-31
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
227
Registration Number
NCT05890352
Locations
🇺🇸

SWOG, Portland, Oregon, United States

🇺🇸

Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States

🇺🇸

Saint Joseph Mercy Brighton, Brighton, Michigan, United States

and more 8 locations

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

First Posted Date
2023-05-19
Last Posted Date
2023-10-17
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Registration Number
NCT05867030

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

First Posted Date
2023-05-16
Last Posted Date
2024-11-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
50
Registration Number
NCT05861050
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

First Posted Date
2023-05-09
Last Posted Date
2023-11-29
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
30
Registration Number
NCT05849610
Locations
🇪🇸

Hospital Doce de Octubre, Madrid, Spain

🇪🇸

Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

🇪🇸

Hospital Virgen de la Arrixaca, Murcia, Spain

and more 7 locations

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

First Posted Date
2023-05-08
Last Posted Date
2023-11-29
Lead Sponsor
University of Birmingham
Target Recruit Count
284
Registration Number
NCT05848765
Locations
🇬🇧

Cardiff and vale University LHB, Cardiff, United Kingdom

🇬🇧

Belfast Health & Social Care Trust, Belfast, United Kingdom

🇬🇧

NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2
Recruiting
Conditions
Marginal Zone Lymphoma
Interventions
Drug: Obinutuzumab
Drug: lenalidomide
First Posted Date
2023-05-06
Last Posted Date
2023-07-19
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
59
Registration Number
NCT05846750
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tian, China

VitD3 Supplementation in Patients With Multiple Myeloma

First Posted Date
2023-05-06
Last Posted Date
2024-02-15
Lead Sponsor
Amany Keruakous, MD, MS.
Target Recruit Count
100
Registration Number
NCT05846880
Locations
🇺🇸

Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy